gsk2269557 has been researched along with Asthma* in 2 studies
1 trial(s) available for gsk2269557 and Asthma
| Article | Year |
|---|---|
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Phosphoinositide 3-kinase Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Phosphatidylinositol 3-Kinases; Piperazines; Vital Capacity; Young Adult | 2018 |
1 other study(ies) available for gsk2269557 and Asthma
| Article | Year |
|---|---|
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (GSK2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation. Topics: Administration, Inhalation; Animals; Asthma; Female; Humans; Indazoles; Indoles; Isoenzymes; Male; Microsomes; Molecular Docking Simulation; Ovalbumin; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Tract Diseases; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Th2 Cells | 2015 |